4.7 Article

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease

Journal

BLOOD
Volume 128, Issue 20, Pages 2450-2456

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-07-728063

Keywords

-

Categories

Funding

  1. National Institutes of Health, National Heart, Lung, Blood Institute (NHLBI) [R01-HL105914, R01-HL87690]
  2. National Cancer Institute, Department of Health and Human Services [P30-CA015704]
  3. National Institutes of Health/National Cancer Institute (NCI) [P30CA016056]
  4. National Institute of Allergy and Infectious Diseases [5U24-CA076518]
  5. Health Resources and Services Administration [HHSH250201200016C]
  6. Office of Naval Research [N00014-14-1-0028, N00014-15-1-0848]
  7. Alexion and Amgen, Inc.
  8. Be the Match Foundation
  9. Bristol Myers Squibb Oncology
  10. Celgene Corporation
  11. Chimerix, Inc.
  12. Fred Hutchinson Cancer Research Center
  13. Gamida Cell Ltd
  14. Genentech Inc
  15. Genzyme Corporation
  16. Gilead Sciences Inc
  17. Health Research Inc
  18. Roswell Park Cancer Institute
  19. HistoGenetics Inc
  20. Incyte Corporation
  21. Jazz Pharmaceuticals Inc
  22. Jeff Gordon Children's Foundation
  23. Leukemia & Lymphoma Society
  24. Medical College of Wisconsin
  25. Merck Co Inc
  26. Mesoblast
  27. Millennium
  28. Takeda Oncology Co
  29. Miltenyi Biotec Inc
  30. National Marrow Donor Program
  31. Neovii Biotech NA Inc
  32. Novartis Pharmaceuticals Corporation
  33. Onyx Pharmaceuticals
  34. Optum Healthcare Solutions Inc
  35. Otsuka America Pharmaceutical Inc
  36. Otsuka Pharmaceutical Co Ltd Japan
  37. Oxford Immunotec
  38. Perkin Elmer Inc
  39. Pharmacyclics
  40. Sanofi US
  41. Seattle Genetics
  42. Sigma-tau Pharmaceuticals
  43. Spectrum Pharmaceuticals Inc
  44. St. Baldrick's Foundation
  45. Sunesis Pharmaceuticals Inc
  46. Swedish Orphan Biovitrum Inc
  47. Telomere Diagnostics Inc
  48. TerumoBCT
  49. Therakos Inc
  50. University of Minnesota
  51. 7Wellpoint, Inc
  52. National Institutes of Health, NHLBI [R01 HL102278]
  53. NCI [5U10HL069294]
  54. NHLBI

Ask authors/readers for more resources

Previous studies have identified single-nucleotide polymorphisms (SNPs) associated with the risk of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation. The current study determined whether these associations could be replicated in large cohorts of donors and recipients. Each SNP was tested with cohorts of patients having the same donor type (HLA-matched related, unrelated, or both) reported in the original publication, and testing was limited to the same genome (recipient or donor) and genetic model (dominant, recessive, or allelic) reported in the original study. The 21 SNPs reported in this study represent 19 genes, and the analysis encompassed 22 SNP association tests. The hazard ratio (HR) point estimates and risk ratio point estimates corresponding to odds ratios in previous studies consistently fall outside the 95% confidence intervals of HR estimates in the current study. Despite the large size of the cohorts available for the current study, the 95% confidence intervals for most HRs did not exclude 1.0. Three SNPs representing CTLA4, HPSE, and IL1R1 showed evidence of association with the risk of chronic GVHD in unrelated donor-recipient pairs from 1 cohort, but none of these associations was replicated when tested in unrelated donor-recipient pairs from an independent cohort. Two SNPs representing CCR6 and FGFR1OP showed possible associations with the risk of chronic GVHD in related donor-recipient pairs but not in unrelated donor-recipient pairs. These results remain to be tested for replication in other cohorts of related donor-recipient pairs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available